The role of ABC transporters in clinical practice

Oncologist

Volumn 8, Issue 5, 2003, Pages 411-424

  Leonard, Gregory D ^a   Fojo, Tito ^a   Bates, Susan E ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Experimental Therapeutics Branch   (United States)

Author keywords

ABC transporter; Cancer; Chemotherapy; Clinical trial; Multidrug resistance

Indexed keywords

ABC TRANSPORTER; AMIODARONE; ANTINEOPLASTIC AGENT; BIRICODAR; CISPLATIN; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLYCOPROTEIN P; IFOSFAMIDE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PHENOTHIAZINE DERIVATIVE; PROTEIN INHIBITOR; QUINIDINE; TAMOXIFEN; TARIQUIDAR; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VINCRISTINE; VINDESINE;

AREA UNDER THE CURVE; BREAST CARCINOMA; CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COLON CARCINOMA; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG METABOLISM; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; INHIBITION KINETICS; KIDNEY CARCINOMA; LEUKEMIA; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RHABDOMYOSARCOMA; TREATMENT OUTCOME; UPREGULATION;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; P-GLYCOPROTEIN;

EID: 0141888537     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.8-5-411     Document Type: Review

References (114)

1. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
2. Breathnach OS, Freidlin B, Conley B et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001;19:1734-1742.
3. Mitscher LA, Pillai SP, Gentry EJ et al. Multiple drug resistance. Med Res Rev 1999;19:477-496.
4. Griffin JD. Resistance to targeted therapy in leukaemia. Lancet 2002;359:458-459.
5. Rosell R, Monzo M, Alberola V et al. Determinants of response and resistance to cytotoxics. Semin Oncol 2002;29(suppl 4):110-118.
6. Shen D, Pastan I, Gottesman MM. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res 1998;58:268-275.
7. Tamm I, Schriever F, Dorken B. Apoptosis: implications of basic research for clinical oncology. Lancet Oncol 2001;2:33-42.
8. Nitiss JL, Beck WT. Antitopoisomerase drug action and resistance. Eur J Cancer 1996;32A:958-966.
9. Zhang K, Mack P, Wong KP. Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int J Oncol 1998;12:871-882.
10. Burchenal JH, Robinson E, Johnston SF et al. The induction of resistance to 4-amino-N10-methyl-pteroylglutaminic acid in a strain of transmitted mouse leukemia. Science 1950;111:116-117.
11. Dano K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 1973;323:466-483.
12. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-162.
13. Ueda K, Clark DP, Chen CJ et al. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem 1987;262:505-508.
14. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001;11:1156-1166.
15. Sauna ZE, Smith MM, Muller M et al. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 2001;33:481-491.
16. Avendano C, Menendez JC. Inhibitors of multidrug resistance to antitumor agents (MDR). Curr Med Chem 2002;9:159-193.
17. Cole SP, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-1654.
18. Borst P, Evers R, Kool M et al. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-1302.
19. Loe DW, Deeley RG, Cole SP. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res 1998;58:5130-5136.
20. Kool M, de Haas M, Scheffer GL et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1) in human cancer cell lines. Cancer Res 1997;57:3537-3547.
21. Zeng H, Bain LJ, Belinsky MG et al. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res 1999;59:5964-5967.
22. Schuetz JD, Connelly MC, Sun D et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999;5:1048-1051.
23. Kruh GD, Zeng H, Rea PA et al. MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr 2001;33:493-501.
24. Belinsky MG, Chen ZS, Shchaveleva I et al. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res 2002;62:6172-6177.
25. Brangi M, Litman T, Ciotti M et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999;59:5938-5946.
26. Childs S, Yeh RL, Georges E et al. Idenfificafion of a sister gene to P-glycoprotein. Cancer Res 1995;55:2029-2034.
27. Vulevic B, Chen Z, Boyd JT et al. Cloning and characterization of human adenosine 5′-triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2). Cancer Res 2001;61:3339-3347.
28. List AF, Spier CS, Grogan TM et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996;87:2464-2469.
29. Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 2000;27(suppl 11):46-52; discussion 92-100.
30. Chen CC, Meadows B, Regis J et al. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin Cancer Res 1997;3:545-552.
31. Fojo AT, Ueda K, Slamon DJ et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84:265-269.
32. Han K, Kahng J, Kim M et al. Expression of functional markers in acute nonlymphoblastic leukemia. Acta Haematol 2000;104:174-180.
33. Leith CP, Kopecky KJ, Chen IM et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood 1999;94:1086-1099.
34. Broxterman HJ, Sonneveld P, van Putten WJ et al. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy. Leukemia 2000;14:1018-1024.
35. Nooter K, Burger H, Stoter G. Multidrug resistance-associated protein (MRP) in haematological malignancies. Leuk Lymphoma 1996;20:381-387.
36. Consoli U, Santonocito A, Stagno F et al. Multidrug resistance mechanisms in chronic lymphocytic leukaemia. Br J Haematol 2002;116:774-780.
37. Borg AG, Burgess R, Green LM et al. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 1998;103:1083-1091.
38. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997;89:917-931.
39. Chung HC, Rha SY, Kim JH et al. P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 1997;42:65-72.
40. Chevillard S, Pouillart P, Beldjord C et al. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 1996;77:292-300.
41. Young LC, Campling BG, Voskoglou-Nomikos T et al. Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin Cancer Res 1999;5:673-680.
42. Joly F, Mangioni C, Nicoletto M et al. A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. Proc Am Soc Clin Oncol 2002;21:202a.
43. Chan HSL, Grogan TM, DeBoer G et al. Diagnosis and reversal of multidrug resistance in paediatric cancers. Eur J Cancer 1996;32A:1051-1061.
44. Clifford SC, Neal DE, Lunec J. High level expression of the multidrug resistance (MDR1) gene in the normal bladder urothelium: a potential involvement in protection against carcinogens? Carcinogenesis 1996;17:601-604.
45. Clifford SC, Neal DE, Lunec J. Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder. Br J Cancer 1996;73:659-666.
46. Tada Y, Wada M, Migita T et al. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int J Cancer 2002;98:630-635.
47. Park J, Shinohara N, Liebert M et al. P-glycoprotein expression in bladder cancer. J Urol 1994;151:43-46.
48. Nakagawa M, Emoto A, Nasu N et al. Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer. J Urol 1997;157:1260-1264; discussion 1264-1265.
49. Toth K, Vaughan MM, Peress NS et al. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am J Pathol 1996;149:853-858.
50. Diestra JE, Scheffer GL, Catala I et al. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tamours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002;198:213-219.
51. Choi KH, Chen CJ, Kriegler M et al. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 1988;53:519-529.
52. Schinkel AH, Smit JJ, van Tellingen O et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
53. Tsuruo T, Iida H, Tsukagoshi S et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhancing cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-1972.
54. Sonneveld P, Durie BG, Lokhorst HM et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet 1992;340:255-259.
55. Sonneveld P, Schoester M, de Leeuw K. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. J Clin Oncol 1994;12:1584-1591.
56. Sonneveld P, Suciu S, Weijermans P et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br J Haematol 2001;115:895-902.
57. Dalton WS, Crowley JJ, Salmon SS et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group Study. Cancer 1995;75:815-820.
58. Twentyman PR. Cyclosporins as drug resistance modifiers. Biochem Pharmacol 1992;43:109-117.
59. Bates SE. Solving the problems of multidrug resistance: ABC transporters in clinical oncology. In: Holland IB, Cole SP, Kuchler K et al., eds. ABC Proteins: From Bacteria to Man. London: Elsevier Science, 2002:359-391.
60. Toppmeyer D, Seidman AD, Pollak M et al. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res 2002;8:670-678.
61. Bramwell VH, Morris D, Ernst DS et al. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res 2002;8:383-393.
62. Bates SE, Chen C, Robey R et al. Reversal of multidrug resistance: lessons from clinical oncology. 2002 Mechanisms of Drug Resistance in Epilepsy: Lessons from Oncology. Novartis Foundation Symposium 243. Chichester: Wiley, 2002:83-102.
63. Fracasso PM, Westervelt P, Fears CL et al. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. J Clin Oncol 2000;18:1124-1134.
64. + lymphocytes after oral and intravenous administration. Clin Cancer Res 2000;6:4186-4191.
65. + cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. Blood 1999;93:306-314.
66. Peck RA, Hewett J, Harding MW et al. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 2001;19:3130-3141.
67. 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res 2003;9:650-656.
68. Ciarmiello A, Del Vecchio S, Silvestro P et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998;16:1677-1683.
69. List AF, Kopecky KJ, Willman CL et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001;98:3212-3220.
70. Solary E, Witz B, Caillot D et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 1996;88:1198-1205.
71. Baer MR, George SL, Dodge RK et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002;100:1224-1232.
72. Belpomme D, Gauthier S, Pujade-Lauraine E et al. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol 2000;11:1471-1476.
73. Millward MJ, Cantwell BM, Munro NC et al. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J Cancer 1993;67:1031-1035.
74. Fracasso PM, Brady MF, Moore DH et al. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 2001;19:2975-2982.
75. Rowinsky EK, Smith L, Wang YM et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 1998;16:2964-2976.
76. Seiden MV, Swenerton KD, Matulonis U et al. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 2002;86;302-310.
77. Beketic-Oreskovic L, Duran GE, Chen G et al. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst 1995;87:1593-1602.
78. Cocker HA, Tiffin N, Pritchard-Jones K et al. In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. Clin Cancer Res 2001;7:3193-3198.
79. List AF, Spier C, Greer J et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993;11:1652-1660.
80. Norton L. Kinetic concepts in the systemic drug therapy of breast cancer. Semin Oncol 1999;26(suppl 2):11-20.
81. Meerum Terwogt JM, Malingre MM, Beijnen JH et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 1999;5:3379-3384.
82. Kruijtzer CM, Schellens JHM, Mezger J et al. Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4508-4516.
83. Kruijtzer CM, Boot H, Beijnen JH et al. Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. Ann Oncol 2003;14:197-204.
84. Leu BL, Huang JD. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 1995;35:432-436.
85. Brinkmann U, Eichelbaum M. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J 2001;1:59-64.
86. Stephens RH, Tanianis-Hughes J, Higgs NB et al. Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-/-) mouse intestine. J Pharmacol Exp Ther 2002;303:1095-1101.
87. Maliepaard M, Scheffer GL, Faneyte IF et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-3464.
88. Kruijtzer CM, Beijnen JH, Rosing H et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 2002;20:2943-2950.
89. Chauncey TR, Rankin C, Anderson JE et al. A phase 1 study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a Southwest Oncology Group study 9617. Leuk Res 2000;24:567-574.
90. Zhou DC, Zittoun R, Marie JP. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 1995;9:1661-1666.
91. Legrand O, Simonin G, Beauchamp-Nicoud A et al. Simultaneous activity of MRP1 and P-gp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 1999;94:1046-1056.
92. Grogan TM, Spier CM, Salmon SE et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993;81:490-495.
93. Abbaszadegan MR, Futscher BW, Klimecki WT et al. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoeitic cells. Cancer Res 1994;54:4676-4679.
94. Filipits M, Suchomel RW, Dekan G et al. MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 1996;2:1231-1237.
95. Mechetner E, Kyshtoobayeva A, Zonis S et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 1998;4:389-398.
96. Galimberti S, Marchetti A, Buttitta F et al: Multidrug resistance related genes and p53 expression in human non small cell lung cancer. Anticancer Res 1998;18:2973-2976.
97. van der Zee AG, Hollema H, Suurmeijer AJ et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995;13:70-78.
98. Yokoyama H, Ishida T, Sugio K et al. Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival. Surg Today 1999;29:1141-1147.
99. Oda Y, Dockhorn-Dworniczak B, Jurgens H et al. Expression of multidrug resistance-associated protein gene in Ewing's sarcoma and malignant peripheral neuroectodermal tumor of bone. J Cancer Res Clin Oncol 1997;123:237-239.
100. Perri T, Fogel M, Mor S et al. Effect of P-glycoprotein expression on outcome in the Ewing family of tumors. Pediatr Hematol Oncol 2001;18:325-334.
101. Abe T, Mori T, Wakabayashi Y et al. Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. J Neurooncol 1998;40:11-18.
102. Tews DS, Nissen A, Kulgen C et al. Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors. J Neurooncol 2000;50:227-237.
103. Riou GF, Zhou D, Ahomadegbe JC et al. Expression of multidrug-resistance (MDR1) gene in normal epithelia and in invasive carcinomas of the uterine cervix. J Natl Cancer Inst 1990;82:1493-1496.
104. Schneider J, Efferth T, Mattern J et al. Immunohistochemical detection of the multi-drug-resistance marker P-glycoprotein in uterine cervical carcinomas and normal cervical tissue. Am J Obstet Gynecol 1992;166:825-829.
105. Ross DD, Karp JE, Chen TT et al. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000;96:365-368.
106. van der Kolk DM, Vellenga E, Scheffer GL et al. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 2002;99:3763-3770.
107. Sargent JM, Williamson CJ, Maliepaard M et al. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol 2001;115:257-262.
108. van den Heuvel-Eibrink MM, Wiemer EA, Prins A et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia 2002;16:833-839.
109. Steinbach D, Sell W, Voigt A et al. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 2002;16:1443-1447.
110. Kanzaki A, Toi M, Nakayama K et al. Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 2001;92:452-458.
111. Faneyte IF, Kristel PM, Maliepaard M et al. Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res 2002;8:1068-1074.
112. Scheffer GL, Pijnenborg AC, Smit EF et al. Multidrug resistance related molecules in human and murine lung. J Clin Pathol 2002;55:332-339.
113. Wishart GC, Bissett D, Paul J et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol 1994;12:1771-1777.
114. Milroy R. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group and the Aberdeen Oncology Group. Br J Cancer 1993;68:813-818.